Avanir Pharmaceuticals (AVNR) Reports In-Line Q2 EPS

Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $28.21 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c